Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer
- 1 October 2012
- journal article
- Published by Elsevier in Human Pathology
- Vol. 43 (10) , 1638-1644
Abstract
No abstract availableKeywords
Funding Information
- Laura and John Arnold Foundation (BC085265, RC2GM092599, U54 CA151668, CA128797)
- U.S. Department of War (BC085265, RC2GM092599, U54 CA151668, CA128797)
- National Institutes of Health (BC085265, RC2GM092599, U54 CA151668, CA128797)
This publication has 29 references indexed in Scilit:
- Regulation of Tumor Angiogenesis by EZH2Cancer Cell, 2010
- Recent advances in managing triple-negative breast cancersF1000 Medicine Reports, 2009
- Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancerAnnals of Oncology, 2009
- Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1Oncogene, 2008
- Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of SwitzerlandAnnals of Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005
- Activated p53 suppresses the histone methyltransferase EZH2 geneOncogene, 2004
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001